GlassScriptPhysician profile
Maria Naples
NPI 1265563084
$1,347.68
in general payments reported to CMS, 2019-2025
18 companies · $185 in 2025
The $185 reported for 2025 was more than what a typical Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $174).
See the full distribution for Psychiatric/Mental Health, Adult (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $390 · 2022: $387 · 2023: $386 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $251.10 | 2021-2025 | Caplyta |
| Abbvie INC. | $237.52 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $119.75 | 2021-2022 | |
| Neuronetics, INC. | $107.91 | 2023 | Neurostar Tms Therapy System |
| Otsuka America Pharmaceutical, INC. | $90.08 | 2021-2025 | Nuedexta, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $86.13 | 2022-2025 | Trintellix |
| Bausch Health US, LLC | $80.31 | 2021-2023 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $66.36 | 2022-2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $61.63 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $51.46 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $47.73 | 2023 | Sunosi, Auvelity |
| Alkermes, INC. | $39.02 | 2025 | Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $23.97 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $22.37 | 2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $19.04 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $15.41 | 2021 | |
| Merck Sharp & Dohme LLC | $14.05 | 2023 | Belsomra |
| Vanda Pharmaceuticals INC. | $13.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Naples listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.